» Articles » PMID: 8548772

Genetic Change in Transforming Growth Factor Beta (TGF-beta) Receptor Type I Gene Correlates with Insensitivity to TGF-beta 1 in Human Prostate Cancer Cells

Overview
Journal Cancer Res
Specialty Oncology
Date 1996 Jan 1
PMID 8548772
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Transforming growth factor beta 1 (TGF-beta 1), a potential regulator of growth of prostate cancer cells, exerts its effects through interaction with membrane receptors. In the present study, an attempt was made to establish a correlation between TGF-beta 1 sensitivity and TGF-beta receptor expression in three prostate cancer cell lines (PC3, DU145, and LNCaP). In a dose-dependent manner, TGF-beta 1 inhibited the proliferation of PC3 and DU145 cells but not LNCaP cells. Since TGF-beta signals through a heteromeric complex composed of TGF-beta receptors type II and type I, the expression of these receptors was investigated by Western blot analysis and reverse transcriptase-PCR. These studies demonstrated that all three prostate cancer cell lines express type II receptor. In contrast, type I receptor was detected only in the TGF-beta 1-sensitive PC3 and DU145 cells but not in the TGF-beta 1-insensitive LNCaP cells. To investigate the possibility that the undetectable expression of type I receptor in LNCaP cells is due to a change in the respective gene, Southern blot analysis was performed. The result demonstrated that there was a genetic change in type I receptor gene in these cells. Subsequently, when LNCaP cells were transiently transfected with T beta R-I cDNA, sensitivity to TGF-beta 1 was restored. These observations indicate that LNCaP cells contain a defective T beta R-I gene which rendered these cells insensitive to the action of TGF-beta 1.

Citing Articles

Cisplatin-induced activation of TGF-β signaling contributes to drug resistance.

Imatsuji S, Ujie Y, Odake H, Imoto M, Itoh S, Tashiro E Oncol Res. 2024; 32(1):139-150.

PMID: 38188677 PMC: 10767239. DOI: 10.32604/or.2023.030190.


Bone morphogenetic proteins, activins, and growth and differentiation factors in tumor immunology and immunotherapy resistance.

Ganjoo S, Puebla-Osorio N, Nanez S, Hsu E, Voss T, Barsoumian H Front Immunol. 2022; 13:1033642.

PMID: 36353620 PMC: 9638036. DOI: 10.3389/fimmu.2022.1033642.


Perspectives of small molecule inhibitors of activin receptor‑like kinase in anti‑tumor treatment and stem cell differentiation (Review).

Cui X, Shang S, Lv X, Zhao J, Qi Y, Liu Z Mol Med Rep. 2019; 19(6):5053-5062.

PMID: 31059090 PMC: 6522871. DOI: 10.3892/mmr.2019.10209.


A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands.

Qin T, Barron L, Xia L, Huang H, Villarreal M, Zwaagstra J Oncotarget. 2016; 7(52):86087-86102.

PMID: 27863384 PMC: 5349899. DOI: 10.18632/oncotarget.13343.


Role of RbBP5 and H3K4me3 in the vicinity of Snail transcription start site during epithelial-mesenchymal transition in prostate cancer cell.

Li D, Sun H, Sun W, Bao H, Si S, Fan J Oncotarget. 2016; 7(40):65553-65567.

PMID: 27566588 PMC: 5323174. DOI: 10.18632/oncotarget.11549.